Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review

Key Takeaways

• Major regulatory milestone: The European Commission has approved teclistamab (TECVAYLI), marking the first BCMA-targeting bispecific antibody approved in the EU for relapsed and refractory multiple myeloma (RRMM) in patients with at least three prior therapies.
• Clinical significance: Teclistamab represents a novel mechanism of action—a bispecific antibody that bridges B-cell maturation antigen (BCMA) on myeloma cells with CD3 on T cells to facilitate T-cell mediated cytotoxicity—addressing a significant unmet need in heavily pretreated patients.
• Market implications: The approval introduces a new treatment option in a competitive landscape that includes other BCMA-targeting therapies and CAR-T cell treatments, with potential to reshape treatment sequencing in RRMM.
• EU harmonization impact: Ongoing Health Technology Assessment (HTA) harmonization initiatives across EU member states are expected to streamline reimbursement pathways for teclistamab and the pipeline competitor elranatamab, potentially accelerating patient access across Europe.

The European Commission has approved teclistamab (TECVAYLI), the first BCMA-targeting bispecific antibody for relapsed and refractory multiple myeloma, marking a significant advancement in EU oncology. The approval applies to patients who have received at least three prior therapies, including an immunomodulatory agent and a proteasome inhibitor. This authorization reflects the European Medicines Agency's (EMA) commitment to expedited assessment of innovative oncology therapies addressing unmet medical needs in heavily pretreated populations. Concurrently, elranatamab, a competing bispecific antibody, remains under regulatory review in the EU, signaling sustained momentum in the bispecific antibody space.

Drug Overview

Teclistamab is a bispecific monoclonal antibody belonging to the class of T-cell redirecting immunotherapies. The drug functions by simultaneously binding to B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and to CD3 on cytotoxic T lymphocytes, thereby bridging tumor cells with effector T cells and facilitating T-cell mediated cytotoxicity. This dual-targeting mechanism distinguishes teclistamab from conventional monoclonal antibodies and provides an alternative approach to CAR-T cell therapies in the BCMA-directed treatment landscape.

Teclistamab (TECVAYLI) is approved for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent and a proteasome inhibitor. The indication reflects the drug's positioning as a salvage therapy for patients with limited remaining treatment options, addressing a critical therapeutic gap in the heavily pretreated RRMM population.

Clinical Insights

Why it matters: Teclistamab's approval was supported by clinical evidence demonstrating efficacy in a patient population with poor prognosis and limited alternative options, underscoring the clinical value of novel bispecific antibody mechanisms in overcoming treatment resistance.

The clinical development program for teclistamab included pivotal trials evaluating efficacy and safety in RRMM patients. While specific trial names, phase designations, and quantitative efficacy endpoints (overall response rate, progression-free survival, hazard ratios, and confidence intervals) were not detailed in the available regulatory information, the approval reflects a positive benefit-risk assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP) based on the totality of clinical evidence.

Safety considerations are particularly relevant for bispecific T-cell redirecting antibodies, as this mechanism of action carries the potential for cytokine release syndrome (CRS) and other T-cell activation-related adverse events. The clinical development program for teclistamab assessed the incidence, severity, and management of such events to establish an appropriate safety profile and inform clinical use recommendations. Detailed grade ≥3 adverse event profiles and risk mitigation strategies were evaluated during the regulatory review process, though specific safety data were not disclosed in the available regulatory summary.

Elranatamab, currently under regulatory review in the EU, represents a competing bispecific antibody in the same therapeutic class. The comparative clinical development of elranatamab versus teclistamab will be important for clinicians and payers assessing treatment options and sequencing strategies in RRMM populations.

Regulatory Context

Teclistamab received European Commission approval as a centralized marketing authorization application (MAA) evaluated through the standard EMA procedure. The centralized procedure ensures harmonized assessment across all EU member states, facilitating uniform market access upon approval. The drug's designation as an innovative therapy addressing an unmet medical need in RRMM likely informed the prioritization and assessment timeline within the CHMP.

The EMA's regulatory framework for bispecific antibodies continues to evolve as more agents in this class advance through development. Teclistamab's approval establishes a regulatory precedent for BCMA-targeting bispecific antibodies in the EU, informing the assessment pathway for subsequent candidates such as elranatamab. The agency's evaluation considered the benefit-risk balance in the context of the heavily pretreated RRMM population, where alternative options are limited and unmet medical need is substantial.

Elranatamab remains under regulatory review in the EU, with anticipated timelines for a Committee for Medicinal Products for Human Use (CHMP) opinion and potential European Commission decision pending completion of the assessment process. The regulatory pathway for elranatamab may benefit from the precedent established by teclistamab's approval, potentially streamlining evaluation and supporting faster market access.

Market Impact

Compared with existing RRMM treatment options including CAR-T cell therapies, conventional monoclonal antibodies, and other BCMA-targeting agents, teclistamab offers a distinct mechanism of action and a non-cell therapy approach that may simplify manufacturing, distribution, and clinical administration. The approval introduces a new competitive dynamic in the EU multiple myeloma market, particularly in the salvage therapy segment for heavily pretreated patients.

The RRMM patient population eligible for teclistamab therapy—those with at least three prior lines of treatment including an immunomodulatory agent and proteasome inhibitor—represents a defined but clinically significant subset of the broader multiple myeloma population. Market penetration will depend on clinical adoption, reimbursement pathways, and pricing negotiations across individual EU member states.

What to watch next: The harmonization of Health Technology Assessment (HTA) processes across EU member states is expected to accelerate reimbursement decisions for both teclistamab and elranatamab, potentially reducing the fragmented market access landscape that has historically delayed patient access to novel oncology therapies in Europe.

Pricing and reimbursement negotiations will be critical determinants of market success in the EU. Bispecific antibodies represent a premium therapeutic category, and payers across EU5 markets (Germany, France, Italy, Spain, and the United Kingdom) will evaluate cost-effectiveness relative to existing RRMM therapies, including CAR-T cells and other BCMA-targeting agents. The outcome of these negotiations will influence market penetration and revenue potential across geographies.

Future Outlook

The regulatory and clinical landscape for bispecific antibodies in multiple myeloma is expected to expand with the anticipated approval of elranatamab and potential label expansions for teclistamab into earlier lines of therapy. Ongoing clinical trials may evaluate teclistamab in combination with other agents, potentially broadening its therapeutic utility and addressing additional patient populations.

EU HTA harmonization initiatives are anticipated to streamline the assessment and reimbursement of novel oncology therapies, including bispecific antibodies. These initiatives aim to reduce the time-to-reimbursement and address variability in patient access across member states, ultimately improving the competitive environment for innovative drugs and facilitating faster market penetration in the EU.

The bispecific antibody pipeline in multiple myeloma continues to expand, with multiple candidates in development targeting BCMA and other tumor-associated antigens. As this class of therapy matures and clinical experience accumulates, treatment algorithms in RRMM are expected to evolve, potentially incorporating bispecific antibodies earlier in the treatment sequence and reshaping the competitive positioning of existing therapies.

Frequently Asked Questions

References

1. European Medicines Agency (EMA). Teclistamab (TECVAYLI) European Commission Approval for Relapsed and Refractory Multiple Myeloma. EMA Regulatory Decision, 2026.

References

1. European Medicines Agency. EMA approval. Accessed 2026-04-30.